Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 31.00K | 60.00K | 0.00 | 110.00K | 0.00 | 0.00 |
Gross Profit | -143.00K | -346.00K | -446.00K | 70.00K | -430.19K | -52.16K |
EBITDA | -3.41M | -3.19M | -6.89M | -9.29M | -7.57M | -18.51M |
Net Income | -4.01M | -7.67M | -7.44M | -9.71M | -8.14M | -18.80M |
Balance Sheet | ||||||
Total Assets | 7.74M | 8.97M | 16.77M | 25.27M | 31.61M | 12.23M |
Cash, Cash Equivalents and Short-Term Investments | 2.36M | 5.92M | 9.71M | 14.22M | 19.51M | 1.74M |
Total Debt | 0.00 | 0.00 | 6.00K | 44.00K | 84.50K | 553.24K |
Total Liabilities | 108.00K | 258.00K | 591.00K | 422.00K | 1.11M | 3.68M |
Stockholders Equity | 7.63M | 8.71M | 16.18M | 24.85M | 30.50M | 8.55M |
Cash Flow | ||||||
Free Cash Flow | -4.22M | -3.80M | -4.85M | -5.68M | -4.31M | -3.74M |
Operating Cash Flow | -4.21M | -3.30M | -4.79M | -5.59M | -3.86M | -2.98M |
Investing Cash Flow | -276.00K | -503.00K | 1.89M | -98.00K | -149.32K | -6.00M |
Financing Cash Flow | -6.00K | 0.00 | -1.60M | 395.00K | 21.78M | 1.63M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | C$13.36M | ― | -8.79% | ― | -0.29% | -53.83% | |
52 Neutral | $7.50B | 0.31 | -61.87% | 2.27% | 17.10% | 1.59% | |
51 Neutral | $9.13M | ― | -63.75% | ― | 9.34% | 69.69% | |
46 Neutral | C$8.37M | ― | -50.76% | ― | ― | -4.84% | |
35 Underperform | C$8.81M | ― | -44.58% | ― | -48.33% | 47.56% | |
$5.28M | ― | ― | ― | ― | |||
$5.36M | ― | ― | ― | ― |
Mountain Valley MD Holdings Inc. has advanced its commercialization strategies across its nutraceutical, agriculture, and husbandry animal sectors, aiming to enhance product efficacy and market reach. The company has strengthened its manufacturing and distribution partnerships, setting the stage for continued growth and increased revenues in 2025.